Semaglutide and tirzepatide are often compared in metabolic research because they engage the incretin system differently. The distinction comes down to how many receptors each one activates.
The key difference
- Semaglutide is a single-receptor agonist — it acts at GLP-1 only.
- Tirzepatide is a dual agonist — it acts at both GIP and GLP-1.
Why it matters in research
Adding GIP activity gives researchers a way to study how a second incretin receptor influences the same metabolic pathways versus GLP-1 activation alone. For the receptors themselves, see GLP-1, GIP & glucagon explained.
Research Use Only. V8 Peptides products are supplied strictly for laboratory research and development and are not intended for human or veterinary use, consumption, or any therapeutic or diagnostic purpose.